BSX · News · 20260824N
Guidance / Outlook
BOSTON SCIENTIFIC CORP · 2026-08-24 · Importance 53 · Surprise 68 · No source text
Boston Scientific updated its 2026 organic sales-growth guidance to 6.5%-8.0%, below its previous double-digit growth forecast. The revised outlook indicates a moderation in expected revenue growth for 2026. The company maintained adjusted EPS guidance of $3.28-$3.32, suggesting continued confidence in profitability and operating efficiency despite slower sales expectations.
Key facts
- Boston Scientific's updated 2026 guidance tempered sales growth expectations to 6.5%-8.0% organically, down from previous double-digit forecasts. source
- Boston Scientific maintained an EPS outlook of $3.28-$3.32 for 2026. source
- Boston Scientific's stock was trading near $50 after the updated 2026 guidance. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | probable | +3.6% | Boston Scientific's updated 2026 guidance tempered sales growth expectations to 6.5%-8.0% organically, down from previous double-digit… |
| net_income | unclear | probable | — | Boston Scientific maintained an EPS outlook of $3.28-$3.32 for 2026. |